JP2019507185A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507185A5
JP2019507185A5 JP2018559177A JP2018559177A JP2019507185A5 JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5 JP 2018559177 A JP2018559177 A JP 2018559177A JP 2018559177 A JP2018559177 A JP 2018559177A JP 2019507185 A5 JP2019507185 A5 JP 2019507185A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
phenyl
membered heterocyclic
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018559177A
Other languages
English (en)
Japanese (ja)
Other versions
JP7098214B2 (ja
JP2019507185A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015749 external-priority patent/WO2017136309A1/en
Publication of JP2019507185A publication Critical patent/JP2019507185A/ja
Publication of JP2019507185A5 publication Critical patent/JP2019507185A5/ja
Application granted granted Critical
Publication of JP7098214B2 publication Critical patent/JP7098214B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018559177A 2016-02-01 2017-01-31 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用 Active JP7098214B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662289463P 2016-02-01 2016-02-01
US62/289,463 2016-02-01
US201662398872P 2016-09-23 2016-09-23
US62/398,872 2016-09-23
PCT/US2017/015749 WO2017136309A1 (en) 2016-02-01 2017-01-31 USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

Publications (3)

Publication Number Publication Date
JP2019507185A JP2019507185A (ja) 2019-03-14
JP2019507185A5 true JP2019507185A5 (https=) 2020-03-12
JP7098214B2 JP7098214B2 (ja) 2022-07-11

Family

ID=58018271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559177A Active JP7098214B2 (ja) 2016-02-01 2017-01-31 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用

Country Status (11)

Country Link
US (1) US11357777B2 (https=)
EP (1) EP3411026B1 (https=)
JP (1) JP7098214B2 (https=)
KR (1) KR20180104123A (https=)
CN (2) CN108697678A (https=)
AU (1) AU2017216429B2 (https=)
BR (1) BR112018015718A2 (https=)
CA (1) CA3012001A1 (https=)
IL (1) IL260701B (https=)
MX (1) MX386216B (https=)
WO (1) WO2017136309A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194386A2 (en) * 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
BR112018015718A2 (pt) 2016-02-01 2019-01-08 Ironwood Pharmaceuticals Inc utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
IL271149B2 (en) * 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
KR20210031931A (ko) * 2018-07-11 2021-03-23 사이클리온 테라퓨틱스, 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
EP3820470B1 (en) * 2018-07-12 2024-09-11 Boehringer Ingelheim International GmbH Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension
CN114555076B (zh) * 2019-10-18 2024-02-02 正大天晴药业集团股份有限公司 用于治疗非酒精性脂肪性肝炎的药物
EP4061352A4 (en) 2019-11-19 2024-02-28 Trevena, Inc. COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS
EP4106741A1 (en) * 2020-02-21 2022-12-28 Universiteit Maastricht Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
CN118525022A (zh) * 2022-01-27 2024-08-20 西藏海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US9260424B2 (en) 2009-10-26 2016-02-16 Auspex Pharmaceuticals, Inc. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
SI2576548T1 (sl) 2010-05-26 2015-11-30 Adverio Pharma Gmbh Uporaba sGC stimulatorjev, sGC aktivatorjev, samih in v kombinacijah s PDE5 inhibitorji za zdravljenje sistemske skleroze
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
CN102164320B (zh) 2011-04-11 2016-06-22 北京数字太和科技有限责任公司 一种改进的基于条件接收技术的终端
SI2970243T1 (sl) * 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
WO2015106268A1 (en) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2015123090A1 (en) * 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3172202B1 (en) * 2014-07-22 2020-01-29 Boehringer Ingelheim International GmbH Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
CA3006746C (en) 2015-11-30 2024-01-30 Ironwood Pharmaceuticals, Inc. Solid dispersions comprising a sgc stimulator
BR112018015718A2 (pt) 2016-02-01 2019-01-08 Ironwood Pharmaceuticals Inc utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
US10925876B2 (en) 2016-05-18 2021-02-23 Merck Sharp & Dohme Corp. Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders

Similar Documents

Publication Publication Date Title
JP2019507185A5 (https=)
DK2041102T3 (en) Inhibitors of human protein tyrosine phosphatase and methods of use
JP2009534425A5 (https=)
JP2019502686A5 (https=)
IL268751B (en) Pharmaceutical preparations for combined treatment
JP2018501276A5 (https=)
BRPI0609101A2 (pt) pteridinas utilizáveis como inibidores de hcv e métodos para a preparação das mesmas
RU2002129569A (ru) Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора
JP2008509187A5 (https=)
JP2018532720A (ja) 線維症の治療のためのセニクリビロック併用療法
RU2009121775A (ru) Пиридильное неароматическое азот-содержащее гетероцикло-1-карбоксилатное производное
JP2003515523A5 (https=)
RU2006136881A (ru) Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv
RU2008141511A (ru) Конденсированные гетероциклические соединения и их применение в качестве модуляторов mglur5
JP2016512547A (ja) 線維症疾患の治療のための化合物
EP2455080A1 (en) S1P1 receptor agonists for use in the treatment of multiple sclerosis
AU2005282290B2 (en) Combination of organic compounds
BRPI0710675A2 (pt) uso de inibidores de c-src em combinação com um composto pirimidilaminobenzamida para o tratamento de leucemia
JP2021518379A5 (https=)
WO2010000030A1 (en) Thiazopyrimidinones and uses thereof
JP2007533730A (ja) 筋炎および筋ジストロフィーを含む炎症性筋疾患を処置するためのc−kit阻害剤の使用法
EP1742633A2 (en) Use of c-kit inhibitors for treating fibrosis
CN112384214A (zh) 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑
RU2019101226A (ru) Ингибиторы wnt для применения при лечении фиброза
WO2005102455A1 (en) Use of c-kit inhibitors for treating plasmodium related diseases